MERSANA THERAPEUTICS INC

Versiunea din 18 septembrie 2024 20:13, autor: Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei MERSANA THERAPEUTICS INC listata cu simbolul US.MRSN ==Descriere companie== Mersana Therapeutics, Inc. (http://www.mersana.com/) is a clinical stage biopharmaceutical company. The Company is focused on developing antibody drug conjugates (ADCs). The Company’s platforms include Dolaflexin and Dolasynthen. Its product candidates include upifitamab rilsodotin (UpRi, XMT-1536) and XMT-1592. The Company’s early stage programs include B7-H4-targeted D...)
(dif) ← Versiunea anterioară | Versiunea curentă (dif) | Versiunea următoare → (dif)

Pagina dedicata companiei MERSANA THERAPEUTICS INC listata cu simbolul US.MRSN

Descriere companieModificare

Mersana Therapeutics, Inc. (http://www.mersana.com/) is a clinical stage biopharmaceutical company. The Company is focused on developing antibody drug conjugates (ADCs). The Company’s platforms include Dolaflexin and Dolasynthen. Its product candidates include upifitamab rilsodotin (UpRi, XMT-1536) and XMT-1592. The Company’s early stage programs include B7-H4-targeted Dolasynthen ADC, XMT-1660, as well as candidates leveraging the Immunosynthen platform. UpRi is an ADC utilizing the Company’s Dolaflexin platform and targeting NaPi2b, which is an antigen broadly expressed in ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma. XMT-1592 uses the Company’s Dolasynthen platform and targets NaPi2b.

Grafic actiuni companieModificare

Ultimele stiri despre MERSANA THERAPEUTICS INC (US.MRSN)Modificare